Body mass and smoking are modifiable risk factors for recurrent bladder cancer

Cancer

Volumn 120, Issue 3, 2014, Pages 408-414

  Wyszynski, Asaf ^a   Tanyos, Sam A ^a   Rees, Judy R ^a   Marsit, Carmen J ^a   Kelsey, Karl T ^b   Schned, Alan R ^a   Pendleton, Eben M ^a   Celaya, Maria O ^a   Zens, Michael S ^a   Karagas, Margaret R ^a   Andrew, Angeline S ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

bladder cancer; body mass index; obesity; recurrence; smoking; urothelial cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BODY MASS; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON MUSCLE INVASIVE UROTHELIAL CELL CARCINOMA; OBESITY; OBSERVATIONAL STUDY; POPULATION EXPOSURE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SMOKING; TRANSITIONAL CELL CARCINOMA;

BLADDER CANCER; BODY MASS INDEX; OBESITY; RECURRENCE; SMOKING; UROTHELIAL CELL CARCINOMA;

ADIPOSITY; ADULT; AGED; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 84892915298     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28394     Document Type: Article

References (37)

1. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007; 25: 285-295.
2. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013; 63: 234-241.
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
4. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005; 66 (6 suppl 1): 4-34.
5. Montie J, Shipley W,. Bladder Cancer Including Upper Tract Tumors and Transitional Cell Carcinoma of the Prostate. National Comprehensive Cancer Network Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2004. www.nccn.org
6. Silverman DT, Morrison AS, Devesa SS,. Bladder cancer. In:, Schottenfeld D, Fraumeni JF, editors. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 1996: 1156-1179.
7. Honma I, Masumori N, Sato E, et al. Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology. 2004; 64: 744-748.
8. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R,. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003; 21: 1315-1330.
9. Schmitz-Drager BJ,. Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications. Eur Urol. 2011; 60: 721-723.
10. Strope SA, Montie JE,. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol. 2008; 180: 31-37.
11. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer. 1999; 86: 2192-2145.
12. Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA,. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol. 2011; 60: 713-720.
13. Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF,. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int. 2002; 90: 228-239.
14. Koebnick C, Michaud D, Moore SC, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1214-1221.
15. Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS,. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer. 2007; 120: 140-146.
16. Inamoto T, Komura K, Watsuji T, Azuma H,. Specific body mass index cut-off value in relation to survival of patients with upper urinary tract urothelial carcinomas. Int J Clin Oncol. 2012; 17: 256-262.
17. Latchamsetty KC, Porter CR,. Treatment of upper tract urothelial carcinoma: a review of surgical and adjuvant therapy. Rev Urol. 2006; 8: 61-70.
18. Umbreit EC, Crispen PL, Shimko MS, Farmer SA, Blute ML, Frank I,. Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. Cancer. 2010; 116: 3399-3407.
19. Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B,. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect. 1998; 106 (suppl 4): 1047-1050.
20. Andrew AS, Gui J, Sanderson AC, et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009; 125: 527-539.
21. Larsson SC, Andersson SO, Johansson JE, Wolk A,. Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer. 2008; 44: 2655-2660.
22. Mydlo JH,. The impact of obesity in urology. Urol Clin North Am. 2004; 31: 275-287.
23. Jayachandran J, Banez LL, Aronson WJ, et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009; 115: 5263-5271.
24. Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG,. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2001; 4: 101-105.
25. Berry PA, Maitland NJ, Collins AT,. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol Cell Endocrinol. 2008; 288: 30-37.
26. Mydlo JH, Gerstein MI, Harris CF, Braverman AS,. Immune function, mitogenicity, and angiogenic growth factor concentrations in lean and obese rodent sera: implications in obesity-related prostate tumor biology. Prostate Cancer Prostatic Dis. 2003; 6: 286-289.
27. Kassouf W, Brown GA, Black PC, et al. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 2008; 180: 1146-1153.
28. Szarvas T, Jager T, Droste F, et al. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res. 2009; 15: 193-201.
29. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N,. Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008; 105: 956-964.
30. Godbout JP, Glaser R,. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J Neuroimmune Pharmacol. 2006; 1: 421-427.
31. Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA,. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol. 2008; 83: 774-784.
32. Choi JM, Cho YC, Cho WJ, Kim TS, Kang BY,. Hydroquinone, a major component in cigarette smoke, reduces IFN-gamma production in antigen-primed lymphocytes. Arch Pharm Res. 2008; 31: 337-341.
33. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol. 2012; 30: 164-171.
34. Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1244-1259.
35. Dirat B, Bochet L, Escourrou G, Valet P, Muller C,. Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocr Dev. 2010; 19: 45-52.
36. Gillum RF, Sempos CT,. Ethnic variation in validity of classification of overweight and obesity using self-reported weight and height in American women and men: the Third National Health and Nutrition Examination Survey. Nutr J. 2005; 4: 27.
37. Noyes K, Singer EA, Messing EM,. Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors. Curr Opin Urol. 2008; 18: 533-539.